How much are patients willing to pay to avoid postoperative nausea and vomiting?

Tong J. Gan, Frank Sloan, Guy De L Dear, Habib E. El-Moalem, David Lubarsky

Research output: Contribution to journalArticle

254 Citations (Scopus)

Abstract

Postoperative nausea and vomiting (PONV) are unpleasant experiences. However, there is no drug that is completely effective in preventing PONV. Whereas cost effectiveness analyses rely on specific health outcomes (e.g., years of life saved), cost-benefit analyses assess the cost and benefit of medical therapy in terms of dollars. We hypothesized that patients were willing to pay for a hypothetical new drug that would eliminate PONV. Eighty elective day surgical patients using general anesthesia participated in the study. After their recovery in the postanesthetic care unit, they were asked to complete an interactive computer questionnaire on demographics, the value of avoiding PONV, and their willingness to pay for an antiemetic. Patients were willing to pay US$56 (US$26-US$97; median, 25%-75%) for an antiemetic that would completely prevent PONV. Patients who developed nausea (n = 21; 26%) and vomiting (n = 9; 11%) were willing to pay US$73 (US$44-US$110) and $100 (US$61-US$200; median, 25%-75%), respectively (P < 0.05). Seventy-six percent of patients considered avoiding postoperative nausea and 78% of patients considered avoiding, vomiting as important (≥50 mm on a 0-100-mm visual analog scale). Nausea or vomiting in the postanesthetic care unit, greater patient income, previous history of PONV, more importance placed on avoiding nausea and vomiting, increasing age, and being married are independent covariates that increase the willingness to pay estimates. Patients associated a value with the avoidance of PONV and were willing to pay between US$56 and US$100 for a completely effective antiemetic.

Original languageEnglish (US)
Pages (from-to)393-400
Number of pages8
JournalAnesthesia and Analgesia
Volume92
Issue number2
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Postoperative Nausea and Vomiting
Vomiting
Antiemetics
Nausea
Cost-Benefit Analysis
Visual Analog Scale
Pharmaceutical Preparations
General Anesthesia
Demography
Health

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

How much are patients willing to pay to avoid postoperative nausea and vomiting? / Gan, Tong J.; Sloan, Frank; De L Dear, Guy; El-Moalem, Habib E.; Lubarsky, David.

In: Anesthesia and Analgesia, Vol. 92, No. 2, 01.01.2001, p. 393-400.

Research output: Contribution to journalArticle

Gan, Tong J. ; Sloan, Frank ; De L Dear, Guy ; El-Moalem, Habib E. ; Lubarsky, David. / How much are patients willing to pay to avoid postoperative nausea and vomiting?. In: Anesthesia and Analgesia. 2001 ; Vol. 92, No. 2. pp. 393-400.
@article{0f229083d0ca466983014213b1cd86a3,
title = "How much are patients willing to pay to avoid postoperative nausea and vomiting?",
abstract = "Postoperative nausea and vomiting (PONV) are unpleasant experiences. However, there is no drug that is completely effective in preventing PONV. Whereas cost effectiveness analyses rely on specific health outcomes (e.g., years of life saved), cost-benefit analyses assess the cost and benefit of medical therapy in terms of dollars. We hypothesized that patients were willing to pay for a hypothetical new drug that would eliminate PONV. Eighty elective day surgical patients using general anesthesia participated in the study. After their recovery in the postanesthetic care unit, they were asked to complete an interactive computer questionnaire on demographics, the value of avoiding PONV, and their willingness to pay for an antiemetic. Patients were willing to pay US$56 (US$26-US$97; median, 25{\%}-75{\%}) for an antiemetic that would completely prevent PONV. Patients who developed nausea (n = 21; 26{\%}) and vomiting (n = 9; 11{\%}) were willing to pay US$73 (US$44-US$110) and $100 (US$61-US$200; median, 25{\%}-75{\%}), respectively (P < 0.05). Seventy-six percent of patients considered avoiding postoperative nausea and 78{\%} of patients considered avoiding, vomiting as important (≥50 mm on a 0-100-mm visual analog scale). Nausea or vomiting in the postanesthetic care unit, greater patient income, previous history of PONV, more importance placed on avoiding nausea and vomiting, increasing age, and being married are independent covariates that increase the willingness to pay estimates. Patients associated a value with the avoidance of PONV and were willing to pay between US$56 and US$100 for a completely effective antiemetic.",
author = "Gan, {Tong J.} and Frank Sloan and {De L Dear}, Guy and El-Moalem, {Habib E.} and David Lubarsky",
year = "2001",
month = "1",
day = "1",
doi = "10.1213/00000539-200102000-00022",
language = "English (US)",
volume = "92",
pages = "393--400",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - How much are patients willing to pay to avoid postoperative nausea and vomiting?

AU - Gan, Tong J.

AU - Sloan, Frank

AU - De L Dear, Guy

AU - El-Moalem, Habib E.

AU - Lubarsky, David

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Postoperative nausea and vomiting (PONV) are unpleasant experiences. However, there is no drug that is completely effective in preventing PONV. Whereas cost effectiveness analyses rely on specific health outcomes (e.g., years of life saved), cost-benefit analyses assess the cost and benefit of medical therapy in terms of dollars. We hypothesized that patients were willing to pay for a hypothetical new drug that would eliminate PONV. Eighty elective day surgical patients using general anesthesia participated in the study. After their recovery in the postanesthetic care unit, they were asked to complete an interactive computer questionnaire on demographics, the value of avoiding PONV, and their willingness to pay for an antiemetic. Patients were willing to pay US$56 (US$26-US$97; median, 25%-75%) for an antiemetic that would completely prevent PONV. Patients who developed nausea (n = 21; 26%) and vomiting (n = 9; 11%) were willing to pay US$73 (US$44-US$110) and $100 (US$61-US$200; median, 25%-75%), respectively (P < 0.05). Seventy-six percent of patients considered avoiding postoperative nausea and 78% of patients considered avoiding, vomiting as important (≥50 mm on a 0-100-mm visual analog scale). Nausea or vomiting in the postanesthetic care unit, greater patient income, previous history of PONV, more importance placed on avoiding nausea and vomiting, increasing age, and being married are independent covariates that increase the willingness to pay estimates. Patients associated a value with the avoidance of PONV and were willing to pay between US$56 and US$100 for a completely effective antiemetic.

AB - Postoperative nausea and vomiting (PONV) are unpleasant experiences. However, there is no drug that is completely effective in preventing PONV. Whereas cost effectiveness analyses rely on specific health outcomes (e.g., years of life saved), cost-benefit analyses assess the cost and benefit of medical therapy in terms of dollars. We hypothesized that patients were willing to pay for a hypothetical new drug that would eliminate PONV. Eighty elective day surgical patients using general anesthesia participated in the study. After their recovery in the postanesthetic care unit, they were asked to complete an interactive computer questionnaire on demographics, the value of avoiding PONV, and their willingness to pay for an antiemetic. Patients were willing to pay US$56 (US$26-US$97; median, 25%-75%) for an antiemetic that would completely prevent PONV. Patients who developed nausea (n = 21; 26%) and vomiting (n = 9; 11%) were willing to pay US$73 (US$44-US$110) and $100 (US$61-US$200; median, 25%-75%), respectively (P < 0.05). Seventy-six percent of patients considered avoiding postoperative nausea and 78% of patients considered avoiding, vomiting as important (≥50 mm on a 0-100-mm visual analog scale). Nausea or vomiting in the postanesthetic care unit, greater patient income, previous history of PONV, more importance placed on avoiding nausea and vomiting, increasing age, and being married are independent covariates that increase the willingness to pay estimates. Patients associated a value with the avoidance of PONV and were willing to pay between US$56 and US$100 for a completely effective antiemetic.

UR - http://www.scopus.com/inward/record.url?scp=0035140502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035140502&partnerID=8YFLogxK

U2 - 10.1213/00000539-200102000-00022

DO - 10.1213/00000539-200102000-00022

M3 - Article

C2 - 11159239

AN - SCOPUS:0035140502

VL - 92

SP - 393

EP - 400

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 2

ER -